<DOC>
	<DOCNO>NCT00002135</DOCNO>
	<brief_summary>To provide oral ganciclovir patient require maintenance control cytomegalovirus ( CMV ) retinitis , lack patent permanent central venous access long-term administration intravenous drug .</brief_summary>
	<brief_title>An Open-Label Safety Study Oral Ganciclovir Maintenance Treatment CMV Retinitis People With Limited Venous Access</brief_title>
	<detailed_description>Patients receive oral ganciclovir maintenance . Patients enrol time closure enrollment receive 2 month study drug undergo follow-up .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Patients must : AIDS . Stable CMV retinitis . Treatment IV ganciclovir IV foscarnet least 18 past 21 day . No permanent central IV catheter present . Had permanent central IV catheter remove two time within past 6 month due catheter infection thrombosis . Consent guardian less legal age consent . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Require continuation concomitant medication preclude protocol . Concurrent Medication : Excluded : Intravitreal antiCMV treatment . Any concomitant medication preclude protocol . Patients follow prior condition exclude : History hypersensitivity acyclovir ganciclovir .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1995</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>